Compare ANNX & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | EVLV |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 994.7M |
| IPO Year | 2020 | 2020 |
| Metric | ANNX | EVLV |
|---|---|---|
| Price | $3.81 | $4.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $15.43 | $9.85 |
| AVG Volume (30 Days) | ★ 3.4M | 2.0M |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.18 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $145,905,000.00 |
| Revenue This Year | N/A | $25.01 |
| Revenue Next Year | N/A | $20.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.48 |
| 52 Week Low | $2.54 | $4.02 |
| 52 Week High | $7.18 | $8.40 |
| Indicator | ANNX | EVLV |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 49.20 |
| Support Level | $3.71 | N/A |
| Resistance Level | $4.37 | $5.21 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 47.12 | 76.06 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.